Bicara Therapeutics Balance Sheet
NASDAQ: BCAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bicara Therapeutics financial position
At the end of fiscal 2025, Bicara Therapeutics reported total assets of $431.0 million, down 15.5% from a year earlier against total liabilities of $29.5 million. Shareholders' equity stood at $401.5 million, or 93.1% of assets. The company held $96.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 14.58, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Bicara Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Cash & Equivalents | 96.69M | 489.71M | 230.44M |
| Short-Term Investments | 318.12M | 0 | — |
| Total Current Assets | 422.05M | 502.53M | 231.07M |
| Property, Plant & Equipment | 330.00K | 155.00K | 202.00K |
| Long-Term Investments | — | 0 | — |
| Total Assets | 430.99M | 510.00M | 233.98M |
| Total Current Liabilities | 28.95M | 17.99M | 15.09M |
| Total Liabilities | 29.54M | 18.12M | 15.47M |
| Shareholders' Equity | 401.45M | 491.88M | -148.77M |
| Retained Earnings | -358.97M | -221.02M | -153.02M |
| Net Cash (Debt) | 414.80M | 489.71M | 230.44M |
| Shares Outstanding | 56.60M | 54.44M | 640.39K |
This table shows 3 annual periods of Bicara Therapeutics's balance sheet, from FY 2025 back to FY 2023, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow BCAX's reporting calendar. What is a balance sheet?